1. Ring J. Neurodermitis - atopisches Ekzem. Vol 1: Thieme Verlag; 2011.
2. Darsow U, Wollenberg A, Simon D, et al. ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol. 2010;24(3):317-328.
3. Kerschenlohr K, Decard S, Darsow U, Ollert M, Wollenberg A. Clinical and
immunologic reactivity to aeroallergens in "intrinsic" atopic dermatitis patients. J Allergy Clin Immunol. 2003;111(1):195-197.
4. Wollenberg A, Kraft S, Oppel T, Bieber T. Atopic dermatitis: pathogenetic mechanisms. Clin Exp Dermatol. 2000;25(7):530-534.
5. J R. Neurodermitis- atopisches Ekzem Vol 1. Thieme Verlag 2011.
6. Akdis CA, Akdis M. Immunological differences between intrinsic and extrinsic types of atopic dermatitis. Clin Exp Allergy. 2003;33(12):1618-1621.
7. Fritsch P. Dermatologie und Venerologie für das Studium. Heidelberg: Springer;
2009.
8. Wollenberg A, Darsow U, Simon D, et al. ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis. Journal of the European Academy of Dermatology and Venereology : JEADV. 2010;24(3):317-328.
9. Wollenberg A, Biedermann T. [Atopic eczema]. Hautarzt. 2018;69(3):190.
10. Lauffer F, Ring J. Target-oriented therapy: Emerging drugs for atopic dermatitis.
Expert opinion on emerging drugs. 2016:1-9.
11. Biedermann T, Werfel T. Status quo und Perspektiven der systemischen Therapie der atopischen Dermatitis. Der Hautarzt. 2015;66(2):108-113.
12. Gu C-Y, Gu L, Dou X. Serum levels of thymus and activation-regulated chemokine can be used in the clinical evaluation of atopic dermatitis. International journal of dermatology. 2015(54):e261-e265.
13. Mansouri Y, Guttman-Yassky E. Immune Pathways in Atopic Dermatitis, and Definition of Biomarkers through Broad and Targeted Therapeutics. J Clin Med.
2015;4(5):858-873.
14. Werfel T, Heratizadeh A, Aberer W, et al. S2k guideline on diagnosis and treatment of atopic dermatitis - short version. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2016;14(1):92-105.
15. Schmitt J, Langan S, Deckert S, et al. Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation. J Allergy Clin Immunol.
2013;132(6):1337-1347.
16. Wollenberg A, Oranje A, Deleuran M, et al. EADV/ ETFAD eczema task force 2015 position paper on diagnosis and treatment of atopic Dermatitis in adult and pediatric patients JEADV. 2015;J Eur Acad Dermatol Venerol.
17. Werfel T, Claes C, Kulp W, Greiner W, von der Schulenberg GJ-M. Therapie der Neurodermitis. In: Information DAfHdDIfMDu, ed. 1 ed. Köln: Deutsches Institut für medizinische Dokumentation und Information; 2006.
18. Klotz U, Teml A, M S. Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet. 2007;46(8):645-660.
19. Darsow U, Wollenberg A, Simon D, et al. Difficult to control atopic dermatitis.
World Allergy Organ J. 2013;6(1):6.
20. Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol. 2018;32(6):850-878.
21. Knop M, Gurtler A, Heratizadeh A, Aszodi N, Werfel T, Wollenberg A. [Topical therapy for atopic eczema]. Hautarzt. 2018;69(3):210-216.
22. Wollenberg A, Bieber T. Proactive therapy of atopic dermatitis--an emerging concept. Allergy. 2009;64(2):276-278.
23. Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71(2):327-349.
24. Tokura Y. Extrinsic and intrinsic types of atopic dermatitis. J Dermatol Science.
2010:58:51–57. doi: 10.1016/j.jdermsci.2010.1002.1008.
25. Wollenberg A, Ehmann LM. Long term treatment concepts and proactive therapy for atopic eczema. Ann Dermatol. 2012;24(3):253-260.
26. Beck LA, Thaci D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130-139.
27. Pucci N, Novembre E, Cammarata MG, et al. Scoring atopic dermatitis in infants and young children: distinctive features of the SCORAD index. Allergy.
2005;1(60):113-116.
28. Chopra R, Vakharia PP, Sacotte R, et al. Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis. Br J Dermatol. 2017;177(5):1316-1321.
29. Gelmetti C, Colonna C. The value of SCORAD and beyond. Towards a standardized evaluation of severity? Allergy. 2004;59 Suppl 78:61-65.
30. Harari M, Dreiher J, Czarnowicki T, Ruzicka T, Ingber A. SCORAD 75: a new metric for assessing treatment outcomes in atopic dermatitis. J Eur Acad Dermatol
Venereol. 2012;26(12):1510-1515.
31. Oranje AP. Practical issues on interpretation of scoring atopic dermatitis:
SCORAD Index, objective SCORAD, patient-oriented SCORAD and Three-Item Severity score. Curr Probl Dermatol. 2011;41:149-155.
32. Silverberg JI, Garg NK, Paller AS, Fishbein AB, Zee PC. Sleep disturbances in adults with eczema are associated with impaired overall health: a US population-based study. J Invest Dermatol. 2015;135(1):56-66.
33. Reich A, Heisig M, Phan NQ, et al. Visual analogue scale: evaluation of the
instrument for the assessment of pruritus. Acta Derm Venereol. 2012;92(5):497-501.
34. Phan NQ, Blome C, Fritz F, et al. Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta Derm Venereol. 2012;92(5):502-507.
35. MK B, R F, RM G, AY F. The Dermatology Life Quality Index 1994-2007: a comprehensive view of validation data and clinical results. Br J Dermatol.
2008(159):997-1035.
36. Silverberg JI, Gelfand JM, Margolis DJ, et al. Severity strata for POEM, PO-SCORAD, and DLQI in US adults with atopic dermatitis. Ann Allergy Asthma Immunol.
2018;121(4):464-471.
37. Sekhon S, Pope J, Canadian Scleroderma Research G, Baron M. The minimally important difference in clinical practice for patient-centered outcomes including health assessment questionnaire, fatigue, pain, sleep, global visual analog scale, and SF-36 in scleroderma. J Rheumatol. 2010;37(3):591-598.
38. Kong TS, Han TY, Lee JH, Son SJ. Correlation between Severity of Atopic Dermatitis and Sleep Quality in Children and Adults. Ann Dermatol.
2016;28(3):321-326.
39. Haeck IM, ten Berge O, van Velsen SG, de Bruin-Weller MS, Bruijnzeel-Koomen CA, Knol MJ. Moderate correlation between quality of life and disease activity in adult patients with atopic dermatitis. J Eur Acad Dermatol Venereol.
2012;26(2):236-241.
40. Gutgesell C, Heise S, Seubert A, Stichtenoth DO, Frolich JC, Neumann C.
Comparison of different activity parameters in atopic dermatitis: correlation with clinical scores. Br J Dermatol. 2002;147(5):914-919.
41. Chopra R, Vakharia PP, Sacotte R, et al. Relationship between EASI and SCORAD severity assessments for atopic dermatitis. The Journal of allergy and clinical immunology. 2017;140(6):1708-1710 e1701.
42. Holm EA, Wulf HC, Stegmann H, Jemec GB. Life quality assessment among patients with atopic eczema. Br J Dermatol. 2006;154(4):719-725.
43. Ben-Gashir MA, Seed PT, Hay RJ. Quality of life and disease severity are correlated in children with atopic dermatitis. Br J Dermatol. 2004;150(2):284-290.